Combination products – MediPhorum’s ‘state of the nation’ report

12 February 2024
Soroosh Bagheriasl
Senior Account Manager

Combination products are increasingly important, especially for drug delivery applications. They are a cornerstone of healthcare progress, enhancing outcomes and improving patient experience through innovative and efficient treatment solutions that harness the synergies of pharmaceuticals and medical devices. They are a crucial component in navigating the intricate and ever-changing healthcare environment.

The combination products sector faces many challenges that, if overcome, will improve and accelerate drug-device development and positively impact patient lives. A starting point is to understand those challenges.

This is why MediPhorum has published The complexities associated with developing combination products for drug delivery.

Discussions across MediPhorum and the broad combination products community have informed this ‘state of the nation’ report. It presents a comprehensive outline of the challenges associated with developing combination products for drug delivery.

The paper discusses issues such as:

  • The combination products landscape – due to increasing competitive pressures as the market matures, the growth in biosimilars, and the experience of organizations when navigating the device-specific regulatory process, it is becoming common for novel medicine to be introduced initially as part of a combination product
  • Regulatory frameworks – the importance of bringing drug-device combination products to market is not optimally reflected in regulatory frameworks. There needs to be appropriate clarity and consistency in approaches, taking into account the time and cost to market and safety
  • Recruitment, retention, and training – there are challenges in recruiting skilled, device-focused talent into biopharmaceutical organizations due to perceived limited career opportunities and relatively low levels of seniority. These are exacerbated when recruiting into highly technical areas, e.g., 3D modeling of fluid dynamics
  • Organizational factors – those above the senior director level often do not have direct device experience, only pharmaceutical. As well as causing recruitment and retention challenges, this can mean that significant decisions are made without a full understanding of the complexity of device development
  • Scheduling device development relative to drug development programs – device development programs may only start once it is clear that the therapeutic program would enjoy a successful phase 2B study, which puts the device development schedule under pressure and on the critical path.

The combination products landscape is rapidly expanding and incredibly dynamic. These critical medical devices have an increasingly important role in the wider biopharmaceutical market. There are strong signs of improvement, but there is still room for optimization and better integration of device development and device providers into drug programs. Working together, we can make this happen.

MediPhorum provides an agile networking environment connecting medical technology industry experts to enhance effective collaboration and develop progressive solutions to shared industry challenges. It does this by providing a safe space for companies to build their expertise through networking and sharing real-world experiences and case studies.

For more information, download the paper here and contact Soroosh Bagheriasl, Senior Account Manager, at

A major milestone – a harmonized approach to product carbon footprint data
Inaugural BioPhorum Quality face to face – get involved
Forecasting the demand for single-use systems
The new Drug Substance Strategic Value Framework – addressing industry pain points
The results are in – BioPhorum’s survey on sterile filtration integrity testing

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Investigation Digital Workstreams
Peer to peer practical guidance on remote inspections and audits
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
BioPhorum roundals on sugical gloves
A visionary strategic framework for future patient-centric outbound biopharmaceutical supply chains
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Lightbulb And Icons On Colourful Background
BioPhorum environmental sustainability roadmap 2022
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing